JOP20210047A1 - عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه - Google Patents

عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه

Info

Publication number
JOP20210047A1
JOP20210047A1 JOP/2021/0047A JOP20210047A JOP20210047A1 JO P20210047 A1 JOP20210047 A1 JO P20210047A1 JO P20210047 A JOP20210047 A JO P20210047A JO P20210047 A1 JOP20210047 A1 JO P20210047A1
Authority
JO
Jordan
Prior art keywords
symptoms associated
behavioral
prophylactic
salt
therapeutic agent
Prior art date
Application number
JOP/2021/0047A
Other languages
English (en)
Inventor
Ishikawa Dai
Sato Shinji
Maeda Kenji
Nakamura Mai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of JOP20210047A1 publication Critical patent/JOP20210047A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

يتعلق هذا الاختراع بعامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصاحبة لمرض تنكسي عصبي أو الأعراض الاندفاعية المصاحبة للمرض العقلي، والذي يحتوي على المركب 7 - [4 - (4-بنزو [ب] –ثيوفين-4-يل-بيبرازين-1-يل)بوتوكسي]-1 اتش- كينولين-2-ون أو ملحه كمركب فعال او كعنصر فعال.
JOP/2021/0047A 2012-10-25 2012-10-25 عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه JOP20210047A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718305P 2012-10-25 2012-10-25
US201361782467P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JOP20210047A1 true JOP20210047A1 (ar) 2017-06-16

Family

ID=49585556

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2021/0047A JOP20210047A1 (ar) 2012-10-25 2012-10-25 عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
JOP/2013/0313A JOP20130313B1 (ar) 2012-10-25 2013-10-24 عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2013/0313A JOP20130313B1 (ar) 2012-10-25 2013-10-24 عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه

Country Status (22)

Country Link
US (4) US20150272946A1 (ar)
EP (2) EP2911670A1 (ar)
JP (5) JP6329140B2 (ar)
KR (1) KR102245016B1 (ar)
CN (4) CN108578408A (ar)
AR (1) AR093247A1 (ar)
AU (1) AU2013335613B2 (ar)
BR (1) BR112015008759A2 (ar)
CA (1) CA2889196C (ar)
EA (1) EA201590808A1 (ar)
HK (1) HK1212609A1 (ar)
IL (1) IL238402B (ar)
JO (2) JOP20210047A1 (ar)
MX (1) MX371279B (ar)
MY (1) MY180185A (ar)
NZ (1) NZ708321A (ar)
PH (1) PH12015500925A1 (ar)
SG (2) SG10201702828TA (ar)
TW (1) TWI643620B (ar)
UA (1) UA116549C2 (ar)
WO (1) WO2014065437A1 (ar)
ZA (1) ZA201503640B (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062323A2 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
SG11201608766TA (en) * 2014-04-22 2016-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
WO2016115150A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating psychosis associated with parkinson's disease
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN115813887A (zh) 2016-12-20 2023-03-21 罗曼治疗***股份公司 包含阿塞那平的透皮治疗***
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
JPWO2021029020A1 (ar) * 2019-08-13 2021-02-18
WO2021261571A1 (ja) * 2020-06-24 2021-12-30 国立大学法人北海道大学 血液脳脊髄関門保護剤
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2822136B1 (en) * 2013-07-03 2018-08-29 Siemens Aktiengesellschaft Method and arrangement for transferring electrical power for subsea applications

Also Published As

Publication number Publication date
AU2013335613A1 (en) 2015-06-04
JOP20130313B1 (ar) 2021-08-17
MX2015005174A (es) 2015-09-04
JP2018138555A (ja) 2018-09-06
US20150272946A1 (en) 2015-10-01
US20190314367A1 (en) 2019-10-17
CA2889196A1 (en) 2014-05-01
IL238402B (en) 2018-11-29
PH12015500925B1 (en) 2015-06-29
TWI643620B (zh) 2018-12-11
CA2889196C (en) 2021-02-16
US20220370442A1 (en) 2022-11-24
SG10201702828TA (en) 2017-05-30
KR102245016B1 (ko) 2021-04-26
TW201427665A (zh) 2014-07-16
AU2013335613B2 (en) 2018-07-12
CN104755082A (zh) 2015-07-01
AR093247A1 (es) 2015-05-27
JP2023123441A (ja) 2023-09-05
HK1212609A1 (zh) 2016-06-17
JP2015535211A (ja) 2015-12-10
JP2020045345A (ja) 2020-03-26
NZ708321A (en) 2019-03-29
ZA201503640B (en) 2016-08-31
JP6329140B2 (ja) 2018-05-23
EA201590808A1 (ru) 2015-08-31
BR112015008759A2 (pt) 2017-07-04
EP2911670A1 (en) 2015-09-02
MX371279B (es) 2020-01-24
SG11201503152TA (en) 2015-05-28
KR20150074156A (ko) 2015-07-01
US20170258787A1 (en) 2017-09-14
CN108578408A (zh) 2018-09-28
IL238402A0 (en) 2015-06-30
WO2014065437A1 (en) 2014-05-01
EP3848033A1 (en) 2021-07-14
PH12015500925A1 (en) 2015-06-29
UA116549C2 (uk) 2018-04-10
MY180185A (en) 2020-11-24
CN114712360A (zh) 2022-07-08
CN112402421A (zh) 2021-02-26
JP2021181448A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
PH12015500925A1 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
TN2015000278A1 (en) Autotaxin inhibitors
PH12014502324A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
ZA201405436B (en) Herbicide tolerant cotton event pdab4468.19.10.3
WO2013181495A3 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
ZA201402333B (en) Tablet including 7-[4-(4-benzo[b]thiophen-4-yl-piperazin -1-yl)butoxy]-1h-quinolin-2-one or salt thereof
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
HK1205462A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013171764A3 (en) Ophthalmic formulations
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
WO2014056779A8 (de) Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung
WO2012169785A3 (en) Symmetrically structured quinazoline derivatives
EA202193278A1 (ru) Средство для профилактики и/или лечения поведенческих и психотических симптомов, связанных с нейродегенеративным заболеванием, или симптомов импульсивности, связанных с психическим заболеванием, содержащее брекспипразол или его соль
IN2014KN02584A (ar)
GB201206984D0 (en) New therapeutic use
IN2014DE00700A (ar)
WO2014068327A3 (en) Agents for the prevention and/or treatment of central nervous system damage
MD4291C1 (ro) Preparat medicamentos pentru tratamentul otitelor